Cempra, Inc. (Nasdaq: CEMP) is jointly developing solithromycin for the Japanese market in partnership with Toyama Chemical, a subsidiary of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE